Oral Warts – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Benign epidermal lesions known as oral
warts are uncommon manifestations of Human papillomavirus (HPV) infection,
particularly rare in children. These warts can take various forms, including
common, palmer and planter, flat, filiform, and genital warts. A clinical
diagnosis is typically established through a comprehensive patient history and
physical examination, with invasive procedures like histopathological biopsies
or HPV DNA testing being infrequent. Several treatment options are available
for oral warts, although none guarantee consistent effectiveness. Certain
factors, such as kissing or oral-genital contact, poor oral hygiene, and
immunosuppression (e.g., HIV), can heighten the risk of oral HPV transmission.
·
In the United States, approximately 10% of men
and 3.6% of women carry oral HPV infections. The CDC estimates that HPV is
responsible for 70% of throat, tonsil, and base tongue cancers.
Thelansis’s “Oral Warts Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential ORAL WARTS treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Oral Warts across the 8 MM market from the Centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Oral Warts Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment